A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas

European Journal of Cancer

Volumn 48, Issue 16, 2012, Pages 3036-3044

  Cesne, Axel Le ^a   Cresta, Sara ^b   Maki, Robert G ^c   Blay, Jean Yves ^d   Verweij, Jaap ^e   Poveda, Andrés ^f   Casali, Paolo G ^b   Balaña, Carme ^g   Schöffski, Patrick ^h   Grosso, Federica ⁱ   Lardelli, Pilar ^j   Nieto, Antonio ^j   Alfaro, Vicente ^j   Demetri, George D ^k  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d CENTRE LÉON BÉRARD   (France)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^g CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ SC Oncologia SS Antonio and Biagio and C Arrigo General Hospital   (Italy)

^j PHARMAMAR S A   (Spain)

^k HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

Antitumour activity; Chimeric fusion oncoproteins; Chromosomal translocation; Sarcoma; Trabectedin

Indexed keywords

TRABECTEDIN;

ADOLESCENT; ADULT; AGED; ALVEOLAR SOFT PART SARCOMA; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CLEAR CELL SARCOMA; DISEASE CONTROL; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM SARCOMA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYXOSARCOMA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SARCOMA; SIDE EFFECT; SMALL CELL SARCOMA; SYNOVIAL SARCOMA; TRANSLOCATION RELATED SARCOMA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CLINICAL TRIALS, PHASE II AS TOPIC; DIOXOLES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SARCOMA; TETRAHYDROISOQUINOLINES; TIME FACTORS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867579960     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.05.012     Document Type: Article

References (54)

1. F. Mitelman Recurrent chromosome aberrations in cancer Mutat Res 462 2-3 2000 247 253
2. C.R. Antonescu The role of genetic testing in soft tissue sarcoma Histopathology 48 1 2006 13 21
3. American Cancer Society-Statistics-Cancer Facts and Figures, Soft tissue sarcoma. ; 2004.
4. F. Mertens, C.R. Antonescu, and P. Hohenberger Translocation-related sarcomas Semin Oncol 36 4 2009 312 323
5. E.C. Borden, L.H. Baker, and R.S. Bell Soft tissue sarcomas of adults: state of the translational science Clin Cancer Res 9 6 2003 1941 1956
6. S.J. Xia, and F.G. Barr Chromosome translocations in sarcomas and the emergence of oncogenic transcription factors Eur J Cancer 41 16 2005 2513 2527
7. M. Ladanyi, and J.A. Bridge Contribution of molecular genetic data to the classification of sarcomas Hum Pathol 31 5 2000 532 538
8. J. Verweij, and L.H. Baker Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations Eur J Cancer 46 5 2010 863 868
9. R. Garcia-Carbonero, J.G. Supko, and J. Manola Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy J Clin Oncol 22 8 2004 1480 1490
10. A. Yovine, M. Riofrio, and J.Y. Blay Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients J Clin Oncol 22 5 2004 890 899
11. A. Le Cesne, J.Y. Blay, and I. Judson Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial J Clin Oncol 23 3 2005 576 584
12. C. Sessa, F. De Braud, and A. Perotti Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails J Clin Oncol 23 9 2005 1867 1874
13. 2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer Ann Oncol 20 11 2009 1794 1802
14. C.N. Krasner, D.S. McMeekin, and S. Chan A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 12 2007 1618 1624
15. B.J. Monk, T.J. Herzog, and S.B. Kaye Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer J Clin Oncol 28 19 2010 3107 3114
16. B.J. Monk, T.J. Herzog, and S.B. Kaye Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cance J Clin Oncol 29 Suppl. 2011 [abstract 5046]
17. M.D. Michaelson, T. Gilligan, and W. Oh Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC) J Clin Oncol, ASCO Annual Meeting Proceedings 23 No. 16S, Part I of II - June 1 Suppl. 2005 4517
18. J.S. Gurtler, L. Goldstein, and S. Delprete Trabectedin in third line breast cancer: A multicenter, randomized, phase II study comparing two administration regimens J Clin Oncol, ASCO Annual meeting proceedings 23 No. 16S, Part I of II - June 1 Suppl. 2005 625
19. L. Zelek, A. Yovine, and E. Brain A phase II study of Yondelis((R)) (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer Br J Cancer 94 11 2006 1610 1614
20. G.D. Demetri, S.P. Chawla, and M. von Mehren Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules J Clin Oncol 27 25 2009 4188 4196
21. F. Grosso, R.L. Jones, and G.D. Demetri Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study Lancet Oncol 8 7 2007 595 602
22. F. Grosso, R. Sanfilippo, and E. Virdis Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series Ann Oncol 20 8 2009 1439 1444
23. A.A. Sandberg Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma Cancer Genet Cytogenet 155 1 2004 1 24
24. M. D'Incalci, and C.M. Galmarini A review of trabectedin (ET-743): a unique mechanism of action Mol Cancer Ther 9 8 2010 2157 2163
25. C. Forni, M. Minuzzo, and E. Virdis Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors Mol Cancer Ther 8 2 2009 449 457
26. P.G. Casali, R. Sanfilippo, and M. D'Incalci Trabectedin therapy for sarcomas Curr Opin Oncol 22 4 2010 342 346
27. F. Grosso, C. Forni, and R. Frapolli Sensitivity of myxoid-round cell liposarcoma (MRCL) to trabectedin (T) may be related to a direct effect on the fusion transcript J Clin Oncol, ASCO Annual Meeting Proceedings Part I 25 18S 2007 0000
28. G. Germano, R. Frapolli, and M. Simone Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells Cancer Res 70 6 2010 2235 2244
29. A. Gronchi, B.N. Bui, and S. Bonvalot Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma Ann Oncol 2011 10.1093/annonc/mdr265
30. L. Paz-Ares, A. Lopez-Pousa, and A. Poveda Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone Invest New Drugs 30 2 2012 729 740
31. R. Garcia-Carbonero, J.G. Supko, and R.G. Maki Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study J Clin Oncol 23 24 2005 5484 5492
32. G.D. Demetri, J. Manola, and D. Harmon Ecteinascidin-743 (ET-743) Induces Durable Responses and Promising 1-Year Survival Rates in Soft Tissue Sarcomas (STS): Final Results of Phase II and Pharmacokinetic Studies in the U.S.A. Proc Am Soc Clin Oncol, ASCO Annual Meeting 20 2001 1406
33. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1 1981 207 214
34. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New Guidelines to Evaluate the Response to Treatment in Solid Tumors J Natl Cancer I 92 3 2000 205 216
35. G.D. Demetri, J. Blay, and P. Schoffski Outcomes of patients (pts) with advanced soft-tissue sarcomas (STS) treated in clinical trials (CTs) versus expanded access programs (EAPs): A decade of experience with single-agent trabectedin (Tr) J Clin Oncol 705 15 Suppl. 2010 205 216 [abstract No. 10029]
36. M. Van Glabbeke, A.T. van Oosterom, and J.W. Oosterhuis Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study J Clin Oncol 17 1 1999 150 157
37. F.C. Maluf, P. Sabbatini, L. Schwartz, J. Xia, and C. Aghajanian Endometrial stromal sarcoma: objective response to letrozole Gynecol Oncol 82 2 2001 384 388
38. S. Sleijfer, I. Ray-Coquard, and Z. Papai Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043) J Clin Oncol 27 19 2009 3126 3132
39. Graaf T. Van Der, J. Blay, and S.P. Chawla PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy - An EORTC STBSG Global Network Study (EORTC 62072) J Clin Oncol 29 2011 (Suppl.) 2011 [abstr LBA10002]
40. P. Schoffski, I.L. Ray-Coquard, and A. Cioffi Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes Lancet Oncol 12 11 2011 1045 1052
41. S. Kummar, A. Strassberger, and A. Monks An evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS) J Clin Oncol 29 2011 (Suppl.) 2011 [abstract 10001]
42. F. Grosso, P. Dileo, and R. Sanfilippo Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma Eur J Cancer 42 10 2006 1484 1490
43. Grosso F, Jones RL, Blay JY, et al. Trabectedin (T) in Soft Tissue Sarcomas (STS) Carriying a Chromosomal Translocation: an Exploratory Analysis. In: 13th Annual Conective Tissue Oncology Society meeting proceedings, Seattle, WA; 2007, Abstract 900.
44. Chawla T, Mohan V, Chua V, et al. A phase II study of Yondelis (ET-743, Tracectidin) in advanced/metastatic soft-tissue sarcoma. In: 13th CTOS annual meeting 2007, November 1-3, Seattle, WA; 2007.
45. P. Dileo, R. Sanfilippo, and F. Grosso Trabectedin (T) in advanced, pretreated synovial sarcomas (SS): A retrospective analysis of 39 patients (pts) from three European institutions J Clin Oncol, ASCO American Society of Clinical Oncology, 46th Annual Meeting 28 15 Suppl. 2010 705 [abstract 10030]
46. A. Lopez-Gonzalez, B. Cantos, E. Tejerina, and M. Provencio Activity of trabectidin in desmoplastic small round cell tumor Med Oncol 2010 10.1007/s12032-010-9687-9
47. P.J. Grohar, L.B. Griffin, and C. Yeung Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells Neoplasia 13 2 2011 145 153
48. R. Roylance, B. Seddon, and A. McTiernan Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre Clin Oncol (R Coll Radiol) 19 8 2007 572 576
49. P. Dileo, F. Grosso, and M. Casanova Trabectedin (T) in metastatic Ewing's family tumors (EFT) patients (pts) progressing after standard chemotherapy J Clin Oncol, ASCO Annual Meeting Proceedings Part I 25 18s 2007 10040
50. M. Minuzzo, S. Marchini, and M. Broggini Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743 Proc Natl Acad Sci U S A 97 12 2000 6780 6784
51. S. Jin, B. Gorfajn, G. Faircloth, and K.W. Scotto Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation Proc Natl Acad Sci U S A 97 12 2000 6775 6779
52. Le Cesne A, Taron M, Rosell R, et al. Biomarkers of DNA repair efficiency in translocation related sarcoma (TRS) patients treated with trabectedin (T). In: CTOS Connective Tissue Oncology Society 16th annual meeting. Paris, France; 2010.
53. P. Schoffski, M. Taron, and J. Jimeno Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study Eur J Cancer 47 7 2011 1006 1012
54. A. Le Cesne, A. Yovine, and J.Y. Blay A retrospective pooled analysis of trabectedin safety in 1132 patients with solid tumors treated in phase II clinical trials Invest New Drugs 2011